Mukozal Malign Melanom
Özet
Mukozal malign melanom, melanositlerden köken alan, agresif seyirli ve nadir görülen bir dış kutanöz kanser türüdür. Tüm melanom vakalarının yalnızca küçük bir yüzdesini oluşturan bu tümörler, ultraviyole ışınlarından bağımsız olarak solunum, gastrointestinal ve genitoüriner sistemlerin mukozal epitellerinde gelişir. En sık baş ve boyun bölgesinde (özellikle nazal kavite ve paranazal sinüslerde) saptanırken, anorektal ve vulvovajinal alanlarda da ortaya çıkabilmektedir. Genellikle 50-80 yaş aralığındaki ileri yaş gruplarında tanı alan bu hastalığın etiyolojisi tam olarak bilinmemekle birlikte, kutanöz melanomların aksine düşük BRAF (%<10) ve belirgin şekilde yüksek KIT mutasyonu (%25) oranları ile genetik olarak ayrışır. Erken evre ve lokalize hastalıklarda temel küratif tedavi yaklaşımı, negatif cerrahi sınırların hedeflendiği geniş lokal cerrahi eksizyondur. Ancak, tümörün anatomik yerleşim kısıtlılıkları nedeniyle tam rezeksiyon çoğunlukla zordur ve adjuvan radyoterapinin lokal kontrolü artırmasına rağmen genel sağkalıma katkısı belirsizdir. Metastatik veya rezeke edilemeyen evrelerde ise prognoz oldukça kötüdür; tedavide nivolumab ve ipilimumab kombinasyonu gibi immünoterapiler ilk basamakta tercih edilmekte, mutasyon durumuna göre imatinib gibi hedefe yönelik ajanlar veya kemoterapi rejimleri devreye girmektedir.
Mucosal malignant melanoma is an aggressive, rare subtype of non-cutaneous cancer arising from melanocytes located in mucosal surfaces. Accounting for only a small percentage of all melanoma diagnoses, these tumors develop independently of ultraviolet radiation within the mucosal epithelium of the respiratory, gastrointestinal, and genitourinary tracts. While most commonly detected in the head and neck region—specifically within the nasal cavity and paranasal sinuses—they also manifest in anorectal and vulvovajinal regions. Typically diagnosed in elderly populations between 50 and 80 years of age, the exact etiology remains unknown. Distinct from cutaneous melanomas, they exhibit low BRAF mutation rates (<10%) and significantly higher rates of KIT alterations (~25%). For localized disease, the primary curative approach is wide surgical excision aiming for negative margins. However, achieving complete resection is frequently complicated by anatomical constraints, and while adjuvant radiotherapy improves local control, its impact on overall survival remains uncertain. Metastatic or unresectable mucosal melanoma carries a poor prognosis; frontline management prioritizes combination immunotherapies like nivolumab and ipilimumab, while subsequent options include targeted agents like imatinib for KIT-mutated cases or systemic chemotherapy.
Referanslar
López F, Rodrigo JP, Cardesa A, Triantafyllou A, Devaney KO, Mendenhall WM, et al. Update on primary head and neck mucosal melanoma. Head & neck. 2016;38(1):147-55.
Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. International journal of clinical and experimental pathology. 2012;5(8):739-53.
Pandey M, Mathew A, Abraham EK, Ahamed IM, Nair KM. Primary malignant melanoma of the mucous membranes. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 1998;24(4):303-7.
Tas F, Keskin S, Karadeniz A, Dağoğlu N, Sen F, Kilic L, et al. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma. Oncology. 2011;81(5-6):353-8.
Tomicic J, Wanebo HJ. Mucosal melanomas. The Surgical clinics of North America. 2003;83(2):237-52.
Lourenço SV, Fernandes JD, Hsieh R, Coutinho-Camillo CM, Bologna S, Sangueza M, et al. Head and neck mucosal melanoma: a review. The American Journal of dermatopathology. 2014;36(7):578-87.
Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. Journal of the National Comprehensive Cancer Network : JNCCN. 2012;10(3):345-56.
Postow MA, Hamid O, Carvajal RD. Mucosal melanoma: pathogenesis, clinical behavior, and management. Current oncology reports. 2012;14(5):441-8.
DeMatos P, Tyler DS, Seigler HF. Malignant melanoma of the mucous membranes: a review of 119 cases. Annals of surgical oncology. 1998;5(8):733-42.
Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. Journal of the American Academy of Dermatology. 2007;56(5):828-34.
Olla D, Neumeister MW. Mucosal Melanoma. Clinics in plastic surgery. 2021;48(4):707-11.
Yde SS, Sjoegren P, Heje M, Stolle LB. Mucosal Melanoma: a Literature Review. Current oncology reports. 2018;20(3):28.
Spencer KR, Mehnert JM. Mucosal Melanoma: Epidemiology, Biology and Treatment. Cancer treatment and research. 2016;167:295-320.
Cui C, Lian B, Zhou L, Song X, Zhang X, Wu D, et al. Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. Annals of surgical oncology. 2018;25(8):2184-92.
Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, et al. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. European journal of cancer (Oxford, England : 1990). 2017;81:36-44.
Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, et al. Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology. 2019;80(1):208-50.
Elmore JG, Barnhill RL, Elder DE, Longton GM, Pepe MS, Reisch LM, et al. Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ (Clinical research ed). 2017;357:j2813.
Lian B, Cui CL, Zhou L, Song X, Zhang XS, Wu D, et al. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2017;28(4):868-73.
Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664-78.
Ascierto PA, Accorona R, Botti G, Farina D, Fossati P, Gatta G, et al. Mucosal melanoma of the head and neck. Critical reviews in oncology/hematology. 2017;112:136-52.
Patel SG, Prasad ML, Escrig M, Singh B, Shaha AR, Kraus DH, et al. Primary mucosal malignant melanoma of the head and neck. Head & neck. 2002;24(3):247-57.
De Virgilio A, Costantino A, Canzano F, Accorona R, Mercante G, Ferreli F, et al. Regional disease control in sinonasal mucosal melanoma: Systematic review and meta-analysis. Head & neck. 2021;43(2):705-15.
Medina JE, Ferlito A, Pellitteri PK, Shaha AR, Khafif A, Devaney KO, et al. Current management of mucosal melanoma of the head and neck. Journal of surgical oncology. 2003;83(2):116-22.
Nenclares P, Ap Dafydd D, Bagwan I, Begg D, Kerawala C, King E, et al. Head and neck mucosal melanoma: The United Kingdom national guidelines. European journal of cancer (Oxford, England : 1990). 2020;138:11-8.
Grant-Freemantle MC, Lane O'Neill B, Clover AJP. The effectiveness of radiotherapy in the treatment of head and neck mucosal melanoma: Systematic review and meta-analysis. Head & neck. 2021;43(1):323-33.
Samstein RM, Carvajal RD, Postow MA, Callahan MK, Shoushtari AN, Patel SG, et al. Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head & neck. 2016;38(9):1310-7.
Stang A, Streller B, Eisinger B, Jöckel KH. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecologic oncology. 2005;96(1):216-21.
Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature. American journal of obstetrics and gynecology. 1998;178(6):1177-84.
Irvin WP, Jr., Legallo RL, Stoler MH, Rice LW, Taylor PT, Jr., Andersen WA. Vulvar melanoma: a retrospective analysis and literature review. Gynecologic oncology. 2001;83(3):457-65.
Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, et al. Primary malignant melanoma of the vagina. Obstetrics and gynecology. 2010;116(6):1358-65.
Matsuda A, Miyashita M, Matsumoto S, Takahashi G, Matsutani T, Yamada T, et al. Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review. Annals of surgery. 2015;261(4):670-7.
Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, et al. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma research. 2017;27(1):57-64.
Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(10):1239-46.
Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. Jama. 2011;305(22):2327-34.
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(26):3182-90.
D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(2):226-35.
Shoushtari AN, Wagstaff J, Ascierto PA, Butler MO, Lao CD, Marquez-Rodas I, et al. CheckMate 067: Long-term outcomes in patients with mucosal melanoma. American Society of Clinical Oncology; 2020.
Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, et al. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO open. 2021;6(6):100325.
Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016;122(21):3354-62.
Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). European journal of cancer (Oxford, England : 1990). 2019;119:168-78.
Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(21):2904-9.
Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. The Lancet Oncology. 2020;21(4):531-40.
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer discovery. 2017;7(4):400-9.
Yan X, Sheng X, Chi Z, Si L, Cui C, Kong Y, et al. Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(8):881-9.
